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Abstract
Background: Cannabidiol (CBD) is commonly used to manage symptoms in conditions and diseases for which
there is limited clinical research for its application. How consumers arrive and decide to use CBD for medical
treatment, despite lacking clinical evidence, is largely unknown. In this paper, we seek to identify the informational
pathways through which consumers arrive at CBD for medical purposes.
Methods: GoFundMe.com campaigns fundraising to purchase CBD between June 2017 and May 2019 were
collected using the Crowdfunding for Health Research Portal (CHRP). Product descriptions were thematically
analyzed to determine pathways leading to incorporation of CBD into medical treatment. Campaign characteristics
such as fundraising ask, funding received, location, campaign title, description, Facebook shares, and number of
donors were recorded. Specific medical uses of CBD proposed in campaigns were tabulated.
Results: The study identified 164 crowdfunding campaigns primarily from the USA (n=159), with several from
Canada (n=5). The campaigns requested $2,219,284.24 (median, $7000) and raised $610,612.87 (median, $1805) from
6825 donors (median, 26). Many campaigns asked for other treatments or illness-related costs not specific to CBD.
The campaigns were shared 42,299 times on Facebook (median, 156 shares). Three informational pathways were
identified leading to incorporation of CBD into medical treatment, which were self-directed research (n=149),
recommendations from a trusted care provider (n=36), and/or experiential insights shared by someone associated
with or influencing the crowdfunders personal network (n=30). The proposed uses of CBD were for cancer (n=96),
seizure-inducing diseases/conditions (n=48), other/unspecified (n=6), joint/inflammatory diseases (n=6), mental
health disorders (n=3), nervous system diseases (n=3), and autoimmune diseases (n=2).
Conclusions: Our results suggest that consumers crowdfunding come to CBD through internally motivated reasons
versus exposure to advertisements or other forms of marketing. Campaign beneficiaries generally had an unmet
medical need that other forms of treatment were not satisfying. Then, through one or more of the informational
pathways identified, CBD is considered a potential solution.
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Background
Cannabidiol (CBD) is a non-psychoactive cannabinoid
found in the cannabis family of plants (Davis 2019). The
use of CBD for medical purposes has increased dramat-
ically over the past 5 years. In 2014, CBD sales in the
USA were $108 million, increasing to $1.9 billion in
2020 (Mikulic 2019). Increases in CBD medical usage
are in part due to the declassification of CBD products
derived from hemp containing less 0.3% tetrahydro-
cannabinol (THC) as a controlled substance in the USA
due to the signing of the 2018 Farm Bill and legalization
of cannabis in Canada (Banda 2018; Government of
Canada 2018). Limited scientific evidence for CBD exists
for uses such as pain management, depression, cancer
treatment, osteoarthritic disorders, and mental health
conditions (MacKeen 2019; Rabin 2019; Lewis 2019;
Khan et al. 2020; Batalla et al. 2019; Ghabrash et al.
2020; Broyd et al. 2016; Schubart et al. 2014; Blessing
et al. 2015; Lee et al. 2017). There have been numerous
studies with promising results for CBD usage for treat-
ments such as epilepsy and related conditions (Lattanzi
et al. 2018; Iseger and Bossong 2015; Osborne et al.
2017; Honarmand et al. 2019; Ramer et al. 2012; Hunter
et al. 2018; Maayah et al. 2020; Junior et al. 2020; Elliott
et al. 2020; Klotz et al. 2018). Recently, the US Food and
Drug Administration (FDA) approved Epidiolex—a CBD
oral solution for advanced epilepsy treatment (United
States Food and Drug Administration 2018).
Despite advancing research, academics and news out-
lets have expressed concerns over hype—understood as
extreme promotion of a medical treatment or service
above what is justified by evidence of efficacy—sur-
rounding CBD (Caulfield 2019; Friedman 2018; Petrow
2019; Eisenstein 2019; Schraer 2019; Adams 2019). Rep-
resented often as a cure-all and marketed with non-
evidence-based or exaggerated efficacy claims, current
uses of CBD do not align with extant evidence of safety
and efficacy (Caulfield 2019). While regarded as a rela-
tively harmless substance, the hype surrounding CBD is
concerning because persons may spend substantial
amounts of money and choose to forego effective treat-
ment for unproven CBD treatments, relying on un-
proven and potentially inaccurate claims (MacKeen
2019; Burns 2018).
Limited literature exists exploring why people are in-
creasingly trying CBD for a range of ailments. Media dis-
course suggests several possible reasons. First, anecdotal
testimonials, often from celebrities or other persons of in-
fluence, are highly visible and frequently come from what
are perceived to be trustworthy sources. These testimo-
nials document the efficacy of CBD for numerous health
purposes. Claims range from pain relief to chronic disease
treatment such as cancer (25 Famous Celebrities and Ath-
letes Who Use or Endorse CBD, 2019). For example, the
National Football League (NFL) player Rob Gronkowski
has advocated that CBD is the most effective treatment
for his chronic pain resulting from his football career
(Chidley-Hill 2019). Other testimonials include celebrities
such as Kim Kardashian using CBD for anxiety relief and
Duchess Camilla of the UK stating it is ‘fantastic’ when
visiting a London farmers market (Parker 2019; Turril
2019).
Second, CBD is generally safe and not psychoactive;
therefore, the potential negative consequences of trying
CBD are perceived to be slight and its use is seen to be so-
cially acceptable (MacKeen 2019). The non-psychoactive
properties of CBD allow for justification from a wide range
of users who might not openly use products containing
THC or other psychoactive molecules. However, the FDA
warns CBD may cause liver injury, impact fertility in males,
or interact with other drugs, and that the composition,
quality, and safety of CBD products vary by manufacturer
(United States Food and Drug Administration 2020).
Third, CBD is available in formats friendly to con-
sumers and thus attractive and for experimentation. For
example, CBD is available in popular foods (gummies,
cheeseburgers), hygienic products (toothpicks, sham-
poos), and a wide variety of other products (MacKeen
2019; Petrow 2019; Williams 2018; Gavura 2019). While
these routes to trying CBD may partially explain experi-
mentation, the underlying personal reasons people are
trying CBD are likely more complicated and contextual-
ized. Thus, to inform public policy and understand the
hype surrounding CBD for medical purposes, additional
research is needed that considers the personal experi-
ences and narratives of individuals using or considering
trying CBD.
An effective strategy to better understand the informa-
tional pathways that shape decisions regarding CBD
usage is to examine medical crowdfunding campaigns.
Crowdfunding platforms allow users to host fundraising
campaigns for medical purposes and share these cam-
paigns on social media. These campaigns often describe
the personal and medical context of the fund recipient
and offer explanations for their proposed use of funds.
The content is unsolicited, therefore allowing for un-
prompted narratives detailing the point of view of the
fundraiser. Researchers have used crowdfunding data to
explore fundraising needs and motivations for other
groups such as transgender communities, people with
cancer accessing complementary and alternative treat-
ments including cannabinoids, and those seeking stem
cell treatment for autism (Barcelos and Budge 2019;
Zenone et al. 2020; Snyder et al. 2020; Snyder and
Turner 2020). CBD is costly, typically not covered by
public or private insurance, and unaffordable to many,
therefore providing conditions for online fundraising for
CBD using crowdfunding platforms . Thus by using
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crowdfunding campaigner narratives, this analysis seeks
to augment existing research on factors promoting the
use of CBD and identify specific informational pathways
these individuals go through prior to arriving at a deci-
sion to utilize CBD for medical purposes.
Methods
Crowdfunding campaigns on GoFundMe.com contain-
ing the terms ‘cannabidiol’ or ‘CBD’ were retrieved using
an automated web scraper tool. The tool, the Crowd-
funding for Health Research Portal (CHRP), is a data-
base of GoFundMe campaigns that includes campaign
characteristics such as title, category, location, funding
pledged, funded received, Facebook shares, number of
donors, as well as the description and updates. CHRP
has collected campaigns posted to the GoFundMe online
sitemap from April 2019. Our search retrieved 1547
GoFundMe campaigns referencing cannabidiol or CBD.
GoFundMe categories not related to medical uses were
removed from these results (n=1101 remaining) and a
two-year cut off (June 2017 to May 2019) implemented
(n=727 campaigns remaining). We chose these date pa-
rameters to coincide with approximately one year before
and after the initial cannabis legalization date of July 1st,
2018, in Canada and ongoing cannabis legalization dis-
course in the USA (Scotti 2018; Cobb 2019). Geographic
parameters limited campaigns to only Canada and the
USA for these reasons, leaving 596 campaigns. The
first author then reviewed each campaign to deter-
mine inclusion. Campaigns were included if the cam-
paign organizer was directly crowdfunding for CBD
for a medical purpose in humans. The second author
decided inclusion for campaigns flagged by the first
author. After reviewing each campaign, 164 remained.
Campaigns were excluded for not crowdfunding for
CBD (n=372), using CBD for an animal (n=37), legal
issues related to CBD (n=10), campaign text not
available in English (n=6), or outside of the geo-
graphic inclusion area (n=7).
Each author independently reviewed 30 campaign de-
scriptions and met to discuss how the campaigners de-
cided to utilize CBD as a potential treatment option. It
was through this process that a focus on informational
pathways emerged. Three dominant pathways were iden-
tified that led campaigners to try CBD: (1) self-directed
research, (2) recommendation by a trusted care provider,
and/or (3) experiential insights offered from someone
associated with or influencing the personal network. The
first author independently assigned each campaign to a
dominant, and in some cases also secondary, pathway in
a spreadsheet and recorded the medical condition inspir-
ing crowdfunding for CBD. The second and third authors
each audited 25% of campaigns to ensure consistency and
confirm the interpretation of the informational pathways.
Any disagreements identified by the second and third
authors were resolved through discussion. Although
campaigns were posted without an expectation of privacy,
we have protected the details of campaigners as much as
possible by avoiding any identifying descriptors.
Results
The 164 included campaigns requested $2,219,284.24
(median, $7000) and raised $610,613.87 (median, $1805)
from 6825 donors (median, 26). Many campaigns asked
for other treatments or illness-related costs not specific
to CBD. The campaigns were shared 42,299 times on
Facebook (median, 156 shares). Most campaigns origi-
nated in the USA (n=155), with few from Canada (n=9).
The proposed uses of CBD were for managing the symp-
toms of, or seeking a cure for, cancers (n=96), seizure-
inducing diseases/conditions (n=48), other/unspecified
conditions (n=6), joint/inflammatory diseases (n=6),
mental health disorders (n=3), nervous system diseases
(n=3), and autoimmune diseases (n=2) (see Table 1). In
the most prevalent proposed use, cancer, CBD was pro-
posed for curative or primary treatment (n=57), pain/
symptom relief from cancer and cancer treatment (n=
24), enhancing conventional treatment (n=11), and un-
specified uses in 4 campaigns. For the second most
prevalent use, seizure-inducing diseases/conditions, all
campaigns (n=48) were to prevent seizures. Table 1 pro-
vides the intent of using CBD for the other diseases and
conditions.
Self-directed research (n=149) was the most com-
monly observed pathway to trying CBD. This informa-
tional pathway is characterized by the campaigner or a
close loved one undertaking significant self-directed re-
search to identify symptom management strategies or
cures in the context of having limited, ineffective, or no
other options to support their disease or condition. This
self-directed process of reviewing websites and other in-
formational sources then led individuals to pursue the
usage of CBD. This pathway is seen predominantly in
cancer and seizure-inducing diseases and conditions
where no cure exists or symptoms were debilitating. For
example, the family of a young child with frequent sei-
zures found CBD through self-research after repeated
unsuccessful management attempts: ‘We have done re-
search on CBD oil and it is something we are interested
in and believe will help stop the seizures’. A second cam-
paign describes a husband completing significant re-
search on alternative treatments after being told his
wife’s cancer is incurable and thus arriving at CBD: ‘My
wife has small cell cancer of the pancreas. We were told
by doctors that there is nothing more they can do. I have
been investigating alternative therapies and they look
very promising’. Campaigns describing this informa-
tional pathway were additionally characterized by those
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who came to CBD from a hope or desire to treat their
disease or condition using natural or alternative options.
Often, citing the perceived harms of Western medicine
or holding beliefs that the body is adequately prepared
to heal itself. For example, a person with non-small neu-
roendocrine cancer rejected chemotherapy, radiation,
and surgery in favour of a self-researched protocol in-
corporating CBD: ‘I decided to follow a natural treat-
ment protocol which included raw juicing, buying an
oxygen system, daily supplements, CBD oil, lots of
prayer, and travelled near and far seeking natural
treatments’.
Some campaigners tried CBD as a result of a recom-
mendation from a trusted care provider as a key infor-
mation source (n=36). Initial recommendations for CBD
came from both medical practitioners such as physi-
cians, as well as alternative practitioners such as naturo-
paths. Such individuals formed the basis of this
informational pathway. Physicians often recommended
CBD to help control seizures. For example: ‘A new
neurologist along with another one of her doctors has
recommended that we start [recipient] on CBD oil. The
CBD oil has the potential to be life-changing for [recipi-
ent]. We are hopeful that it could help with her seizures’.
Alternative practitioners were observed in some cases
advising patients for natural cancer regimens, usually in
the context of having no other options. For example, a
person with stage 4 breast cancer was crowdfunding
treatment prescribed by a naturopathic oncologist,
which included ‘high doses of RSO, CBD, Vitamin IV
therapy’. There were numerous instances of a trusted
care provider being approached by a person or their
caregiver seeking to try CBD oil but wanting to first en-
sure its safety or efficacy, therefore acting as gatekeepers.
For example: ‘[Rachel]’s family research alternative
methods to try to control her seizures and asked the
doctor about CBD. He was immediately on board with
the ideas and gave her a recommendation for it’.
Experiential insights from someone associated with or
influencing the crowdfunders personal network drew
Table 1 Disease or condition proposed for CBD usage on GoFundMe.com by intended outcome, Facebook shares, donors, total
requested, and total received












5146 888 236,237.7 95,862.21 11
Pain/symptom relief 4049 843 233,476.22 74,227.7 24
Treatment/cure 18,023 3065 1,018,765.54 281,692.77 57
Unspecified 514 76 45,000 12,750 4
Total 27,732 4872 1,533,479.46 464,532.68 96
Seizure inducing diseases/
conditions
Seizure relief 10,937 1306 466,397.35 96,814.44 48
Total 10,937 1306 466,397.35 96,814.44 48
Other/unspecified conditions Pain/symptom relief 587 109 47,555 6753 4
Symptom/pain relief and
seizure relief
101 13 1500 950 1
Unspecified 21 9 50,000 570 1
Total 709 131 99,055 8273 6
Joint/inflammatory diseases/
symptoms
Pain/symptom relief 638 208 52,401.62 12,591.18 4
Treatment/cure 772 72 12,000 7547 2
Total 1410 280 64,401.62 20,138.18 6
Nervous system diseases Pain/symptom relief 69 21 4000 1665 1
Treatment/cure 419 50 19,450.81 4884.57 2
Total 488 71 23,450.81 6549.57 3
Mental health conditions
and disorders
Pain/symptom relief 159 15 11,500 1760 2
Treatment/cure 430 82 16,000 9365 1
Total 589 97 27,500 11,125 3
Autoimmune disorders Treatment/cure 434 68 5000 3180 2
Total 434 68 5000 3180 2
Grand total 42,299 6825 2,219,284.24 610,612.87 164
The table is a summary of crowdfunding campaigns on GoFundMe.com fundraising cannabidiol for medical usage
Zenone et al. Journal of Cannabis Research            (2021) 3:13 Page 4 of 8
some people to CBD (n=30), and this forms the basis of
the third informational pathway identified. CBD recom-
mendations came from a person in the immediate social
network of the person or their caregiver, including fam-
ily, friends, colleagues, and acquaintances. Other recom-
mendations came from someone associated with but not
in the personal network such as strangers (online or in-
person), via social media messages, or from shared on-
line testimonials. An example of someone within the so-
cial network is a daughter who did online research and
recommended to her mom to try CBD: ‘After doing
much research since the beginning of our Mother’s diag-
nosis she [daughter] read on about Cannabis oil and
Rick Simpson’s oil and about people healing themselves
of tumours and cancer by ingesting high levels of THC
and CBD’. Recommendations from outside the personal
network, such as strangers, often reached came through
social media or traditional media such as viewing testi-
monials on television programs. For example, a family
struggling to control the seizures of their youngest
daughter saw an interview on CNN (an American news
network) about a girl who was experiencing over 300
grand mal seizures per week and who found relief from
CBD. The parent responded by making it a mission to
try CBD. In a second case, a family is reached out to on
Facebook with information that CBD is a viable option
for cancer treatment: ‘I had some wonderful ladies pri-
vate message me that are going through the same thing,
have started CBD and some are in remission. There is
hope!’. The exchange led to the family trying and priori-
tizing CBD treatment.
Discussion
Our findings suggest that crowdfunders are basing their
decisions on CBD use primarily from information they
have compiled from their own research to address a ser-
ious health issue, usually not accompanied by medical
advice. That the most commonly observed informational
pathway to CBD use is self-directed research suggests
that most campaigners were satisfied in-part by the evi-
dence or testimonials they find from their online search
strategies. Similarly, those referencing an experiential
insight from another person who has had success with
CBD found the testimonials compelling and were at least
in-part satisfied with the anecdotal information pro-
vided. Only a small number of crowdfunders in our sam-
ple detailed having consulted a qualified medical
provider in their decision.
Campaigners often had few to no perceived effective op-
tions for managing their health, often describing terminal
diagnoses, significant pain, uncontrolled symptoms from
numerous diseases, and/or other issues requiring interven-
tion. Some crowdfunders mentioned emerging research
that CBD may support their condition, as well as many
others. For some of the conditions listed, such as cancer,
there is early, premature research for its possible treat-
ment and therapeutic use (Honarmand et al. 2019; Zhang
et al. 2019; Dariš et al. 2019). The perception of untapped
medical potential made CBD an attractive option as there
was little to nothing for campaigners to lose from experi-
mentation. Other studies have found that many people be-
lieve there is not yet discovered medical potential
(Corroon and Phillips 2018; Tran and Kavuluru 2020).
Amplifying its attractiveness to crowdfunders, many
viewed CBD as a safe, natural substance, absent of psycho-
active properties. News reporting commonly comments
on such perceptions (Rabin 2019; Friedman 2018;
Halperin 2018; Ramanathan 2018). Thus, to crowdfun-
ders, CBD appears to offer a harmless chance of treatment
or symptom relief in the absence of other options.
A significant finding from our study is that those fun-
draising for CBD on GoFundMe.com usually were moti-
vated and pursue CBD through their own initiative
versus exposure to advertisements, the advice of quali-
fied medical professionals, or the opinion of alternative
medical practitioners. Policy responses to regulate or en-
sure the appropriate usage of CBD need to consider that
those using CBD for medical purposes—whether for
pain relief or for treatment of serious illnesses—were
usually people seeking information and arriving at infor-
mational pathways from outside of the medical hier-
archy. To promote retrieval of information from
qualified sources, several evidence-based strategies are
available. These include health literacy interventions, in-
corporation of patient perspectives into treatment deci-
sions, careful media dissemination of new study findings
to avoid sensational reporting, online fact-checking, and
social media campaigns (Trethewey 2020; Hawke et al.
2019; Siminoff 2013; Chou W-YS and Klein 2018).
There were important differences between the infor-
mational pathways of those trying CBD for epilepsy ver-
sus other health conditions referenced in the reviewed
crowdfunding campaigns. There is clinical acceptance
for the use of CBD for epilepsy, primarily for the man-
agement of seizures (United States Food and Drug Ad-
ministration 2018). Those trying CBD for this reason
often incorporated the advice of a medical practitioner
into their treatment decision, as opposed to other uses.
Those utilizing CBD for other symptoms and diagnoses
seemingly made the decision with limited or no clinical
acceptance. For example, those incorporating CBD for
cancer into their treatments commonly presented narra-
tives where their healthcare system did not have any
curative options left for them or the prescribed treat-
ment was ineffective. The usage of CBD was seen as an
alternative option to those offered by a medical system
that had abandoned them. In the most extreme cases,
foregoing accepted medical treatments in favour of CBD
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or relying on CBD for consequential diseases such as
cancer. This finding underscores the importance of pol-
icymakers and medical bodies to provide and dissemin-
ate health literacy materials for the scientifically-
supported uses of CBD.
Several research areas were identified that need further
exploration. First, the information sources that cam-
paigners in our study referenced—blogs, product descrip-
tions, and information websites—need further study so we
can understand their content. This can inform what mes-
sages are being transmitted that lead to CBD experimenta-
tion. Second, our study could not capture the interactions
between campaigners and the in-person conversations
they had with those who work at cannabis dispensaries
(both legal and non-legal) or other providers. Numerous
campaigners in our study reference that they were guided
from knowledgeable persons such as cannabis retail
workers in decision-making around CBD, including dos-
ing, product selection, and method of administration. The
lack of information available around such interactions and
subsequent product selection, including CBD product
form, require further investigation. Future research should
incorporate qualitative interviews into those who help
prospective CBD consumers initiate and guide treatment.
Our study has several limitations. The data collected is
self-reported and the accuracy of campaigns was subject
to the truthfulness of campaigners. There may be infor-
mation selectively omitted to make a compelling case for
donations. Second, our study does not capture all fun-
draising of CBD products for medical purposes. Our
search strategy, while robust, does not capture CBD
products which might go by a different name.
Conclusion
This study explored the informational pathways used by
those fundraising for CBD on GoFundMe with the
intention of incorporating CBD into their medical treat-
ment. After identifying 164 campaigns using CBD for
medical purposes on GoFundMe.com, we discerned that
most potential or current CBD users arrived at the deci-
sion the result of three pathways: self-directed research,
a recommendation from a trusted care provider, or from
the anecdotal experience of another. The medical uses
of CBD were for a variety of purposes, with most being
for cancer or epilepsy. CBD filled an urgent void or need
for most campaigners—in that they had ineffective or no
options, did not trust the other treatment options avail-
able, or wanted a natural treatment option. This infor-
mation should help policy makers and patient advocates
to craft targeted interventions for users of CBD, includ-
ing combatting specific sources and types of misinforma-
tion. Future research is needed to understand which
self-directed sources of information potential CBD users
find and use to inform their treatment decisions.
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